BACKGROUND: Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) represents a major clinical challenge. Optimal treatment strategies for posttransplant recurrence or metastasis remain undefined. METHODS: We retrospectively analyzed 136 LT cases with recurrent or metastatic HCC where systemic therapy was applied in a single high-volume LT center during 2002-2024. Progression-free survival (PFS) and overall survival were evaluated using Kaplan-Meier and Cox models, with additional strategies to address treatment-era effects, including drug-overlap era cohort, restricted targeted therapy-only subgroup, an 8-wk landmark analysis, and overlap-weighted Cox models. RESULTS: First-line therapy included sorafenib (n = 72) and lenvatinib (n = 64). Median PFS (95% confidence interval) was 3.5 mo (3.00-5.70 mo) with sorafenib versus 9.4 mo (6.17-16.07 mo) with lenvatinib (P 100 ng/mL, and modified albumin-bilirubin grade 2, but initial combination locoregional therapy is a protective predictor. CONCLUSIONS: Lenvatinib was associated with improved PFS and fewer severe adverse events compared with sorafenib in post-LT recurrent HCC. Prospective multicenter studies are warranted.
Hsu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: